Deals: Alnylam And Cubist Form Strategic Collaboration To Develop And Commercialize RNAi Therapeutics Targeting Respiratory Syncytial Virus (RSV) Infection

Latest: Watch here for details of new products and services.

About Us: Innovaro Pharmalicensing - Partnering solutions for the life sciences
Our Products: Overview; Partnering Search; Company Profiling; Pay-per-Click New!; Deal Negotiation; PL Intelligence; Reports; Comparison
PL Intelligence: Overview; Industry news; Deals review; Press releases; Articles
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire; Jobs
Contact Innovaro Pharmalicensing: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Innovaro Pharmalicensing
is a division of
Innovaro Europe Ltd

Deals review
Deal details

Alnylam and Cubist Form Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting Respiratory Syncytial Virus (RSV) Infection

In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.

Subscribe now for instant access to the benefits PL Intelligence has to offer. Find out more.

Request a demo of
PL Intelligence

Novartis licenses rights to develop and commercialize new respiratory syncytial virus (RSV) treatment

Alnylam Announces Manufacturing Agreement with DowpharmaSM for RNAi Therapeutics

MedImmune and Biota announce collaboration to develop new therapies for RSV infection

Merck and Alnylam Establish New Strategic Alliance to Co-Develop and Co-Commercialize RNAi Therapeutics for Ocular Diseases

Alnylam initiates RNAi therapeutic program for pandemic Influenza; collaboration with leading flu researchers at University of Georgia

Merck and Alnylam establish strategic alliance to apply RNA interference for human therapeutics

TACERE THERAPEUTICS ENTERS COLLABORATION AND LICENSE AGREEMENT WITH PFIZER TO DEVELOP AND COMMERCIALIZE RNAi HEPATITIS C DRUG

Alnylam grants Nastech a license to develop RNAi therapeutics against TNF-alpha

Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis

Related categories

Therapeutic target

Respiratory

More deals

Clients in focus...

Get the Flash Player to see this rotator.

Press releases: Innovaro Pharmalicensing current industry press releases.

Products:	Partnering Search	Pay-per-Click	Company Profiling	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us

Alnylam and Cubist Form Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting Respiratory Syncytial Virus (RSV) Infection

Related deals

Related categories

More deals

Latest deals

Most viewed deals

By month